Survival and Predictors of Mortality Among Adult HIV/AIDS Patients Initiating Highly Active Antiretroviral Therapy in Debre-Berhan Referral Hospital, Amhara, Ethiopia: A Retrospective Study.

BACKGROUND: Acquired immune deficiency syndrome is one of the most destructive epidemics the world has ever witnessed. An estimated 36.9 million people were living with HIV in 2017. HIV/AIDS is the major contributing factor for morbidity and mortality in low- and middle-income countries. Although different studies on survival and predictors of mortality among HIV/AIDS patients after initiation of antiretroviral therapy were conducted, there are inconsistencies in the findings of those studies. Furthermore, to the authors' knowledge, there was a dearth of studies conducted in this study area.
PURPOSE: The purpose of this study was to assess the survival and predictors of mortality among adult patients starting highly active antiretroviral therapy at Debre Berhan Referral Hospital, North Showa, Amhara, Ethiopia. PATIENTS AND METHODS: An institution-based retrospective study was conducted among the medical records of 447 study subjects' selected using simple random sampling from January 1t, 2013 to December 30, 2018. The data was collected using a structured data abstraction checklist and analyzed using Kaplan-Meier statistics and Cox regression models.
RESULTS: Among 447 adult patients, 54 patients (12.1%) had died, giving a crude death rate of 4.18 per 100 person years (95% CI=3.20-5.45). The overall estimated survival rate after initiation of antiretroviral therapy was 81.7% (95% CI=75.36-86.54%) at 72 months of follow-up. The independent predictors of mortality were clinical stage IV (HR=15.6, 95% CI=6.609-36.948), baseline opportunistic infections (HR=1.86, 95% CI=1.048-3.330), baseline Hgb<10 mg/dL (HR=4.655, 95% CI=2.253-9.619), baseline CD4<200 cells/µL (HR=4.71, 95% CI=2.275-9.751), the presence of comorbidity (HR=2.56 95% CI=1.391-4.740), being widowed (HR=3.475, 95% CI=1.412-8.550), and bedridden functional status (HR=3.069, 95% CI=1.111-8.480).
CONCLUSION: Patients with opportunistic infections, advanced clinical stage disease, bedridden functional status, baseline Hgb<10 mg/dL, baseline CD4<200 cells/µL, and comorbidity should be given special care.

Introduction

Acquired immune deficiency syndrome (AIDS) is among the most destructive epidemics the world has ever witnessed. The United Nations program on HIV/AIDS (UNAIDS) estimated that 36.9 million people were living with HIV (PLWH) in 2017.1 Low- and middle-income countries account for the vast majority of PLWH, with an estimated 25.5 million living in sub-Saharan Africa. Of those, 19.4 million were living in Eastern and Southern Africa, which saw 44% of new HIV infections globally in 2016.2 HIV-related estimates and projections for Ethiopia indicate that the estimated number of adults living with HIV/AIDS was 665,116, with an annual death rate of 12,265 in 2017.3

By the end of 2017, 21 million people were receiving life-saving antiretroviral therapy (ART). A further 15.8 million were expected to start treatment by the WHO “treat all” recommendations to increase survival among PLWH.4,5 In 2003, the Government of Ethiopia introduced its ART program to reduce HIV-related morbidity and mortality, improve the quality-of-life of PLWH, and mitigate some of the impacts of the epidemic.6 Even though the benefit of ART for people living with HIV/AIDS is well established in terms of improving quality-of-life and reducing morbidity and mortality, there is a regional variation in the extent of its benefit.7

Various studies which were conducted in Ethiopia showed that the estimated mortality ranged from 4.2% to 43%, with the majority of deaths occurring within 6 months of initiating ART.8–20 Advanced stage of the disease, non-working functional status, low baseline hemoglobin level, lower baseline weight patients, a CD4 count <200 cells/µL of blood, not taking cotrimoxazole prophylaxis therapy, opportunistic infections, educational status, place of residence, nutrition, and poor ART adherence were commonly identified as predictors of death in HIV. However, the effect of comorbidity on survival and mortality of PLWH has not been studied.

Little was also known about survival and predictors of mortality among HIV-infected patients in the study area. Hence, this study aimed to investigate the outcomes of ART, focused on adults on ART in Debre Berhan Referral Hospital, North Showa Zone, Amhara National Regional State, Ethiopia.

Patients and Methods

Study Design, Area, and Period

An institutional-based retrospective cohort study was conducted from March to April 2019 based on a medical record review of HIV/AIDS patients on HAART enrolled from January 1, 2013 to December 30, 2017, which were followed up to December 30, 2018. The study was conducted at Debre Berhan Referral Hospital, which is 130 km North-East of Addis Ababa. The hospital is in Debre Berhan town, North Showa Zone, Amhara National Regional State, Ethiopia. Debre Berhan Referral Hospital was the only hospital in the North Showa area providing ART in 2007. Since the start of expanded Partnership activities like twinning with the American International Health Alliance over the years to include collaborations between Debre Berhan Referral Hospital, Mehal Meda Hospital, and Enat Hospital, and Debre Berhan University, ART uptake in the region has increased from 1,789 patients at one facility to 5,282 patients at Debre Berhan, four rural hospitals, and 86 area health centers.21 Nowadays, Debre Berhan hospital provides care for a total of 2,005 HIV/AIDS patients.

Study Population

HIV-positive adults aged 15 years or older who started ART at DBRH ART center between January 1, 2013 and December 30 2017 with complete intake forms, registers, and follow-up forms were the study population.

Sample Size and Sampling Technique

The sample size was determined using double population proportion formula by considering CD4 count (≥200 cells/μL with the proportion of 0.047 vs <200 cells/μL with the proportion of 0.084) as an independent predictor based on a study done in Jimma university teaching hospital.22 The sample size was calculated using two-sample proportion formulas in Epi-Info version 7 for Windows.23 The calculation was based on the assumption of type I error of 5%, and power of 80%, providing a sample size of 447.

A simple random sampling technique was used for selecting study subjects among 1,186 patients' cards that were obtained from the ART clinic.

Study Variables

Time to an event in months was the dependent variable. Age, sex, educational status, occupational status, marital status, CD4 count, WHO clinical staging, functional status, hemoglobin level, ART regimens and medications, risk behaviors including substance use, and adherence were the predictor variables.

Data Collection

A standard data abstraction checklist was used for recording information extracted from an electronic and paper-based database and patient cards. This form was developed using the standardized ART entry and follow-up form employed by the ART clinic.

The collected data was preserved in a secure environment to avoid loss and breach of confidentiality. All collected data were cleaned, validated, coded, and stored at the end of each day by the principal investigator. Processing and storing was done both electronically by entering data into epi data version 4.2.

Data Quality Assurance

The quality of data was assured before, during, and after data collection accordingly.

An objective-based and standardized questionnaire was prepared; Pretest on 5% of medical record review was done. Data collectors and supervisors were trained. The collected data was checked for its completeness and before transferring to computer software. A non-overlapping code was given for each question and the coded data were entered and cleaned in Epi data version 4.2.

Data Processing and Analysis

Data was entered using epi data version 4.2 and Statistical analyses were performed using Stata version 15.0. Descriptive statistics such as mean, median, interquartile range (IQR), and standard deviation were used to summarize the characteristics of the cohort. A Kaplan–Meier model was used to estimate the patients` survival after ART initiation, and Log rank tests were used to compare survival curves. The necessary assumption for the model was checked by the Schoenfeld residual test.

Cox proportional hazards regression models were used to identify independent predictors of mortality and calculate hazard ratios. Bi-variable Cox proportional hazards regression was tested first and those independent variables which become fitted on the bi-variable regression at 0.25 level of significance were included in the multivariable analysis.24 Multiple Cox proportional hazards regression was done at the 0.05 level of significance to determine the net effect of each explanatory variable on time to death after initiation of ART. The results of these models were expressed as hazard ratios (HRs) with 95% CI. STROBE cross-sectional reporting guidelines were used to assess the paper components.

Results

Socio-Demographic Characteristics of the Study Participants

Among 1,186 HIV positive adults (≥15 years), who were enrolled from January 1, 2013 to December 30, 2018, 447 patients on ART were followed. Among 447 patients, about two-thirds of study participants were females, 358 (80.1%) were from the urban area. The mean and median age of the cohort at ART initiation was 37 years and 36 years (IQR= 30–44 years), with a SD of ±11 years, respectively (Table 1).

Table 1

Baseline Socio-Demographic Characteristics of Adult HIV/AIDS Patients on ART in DBRH ART Clinic, North Showa, Amhara National Regional State, Ethiopia, 2019 (n=447)

Variables	Category	Vital Status at Last Contact		Total, n (%)
		Censored, n (%)	Death, n (%)
Age of patient	15–24	41 (95.35)	2 (4.65)	43 (9.62)
	25–34	131 (89.12)	16 (10.88)	147 (32.89)
	35–44	122 (83.56)	24 (16.44)	146 (32.66)
	≥45	99 (89.19)	12 (10.81)	111 (24.83)
Sex	Male	129 (87.16)	19 (12.84)	148 (33.11)
	Female	264 (88.29)	35 (11.71)	299 (66.89)
Family size	≤2	107 (88.43)	14 (11.57)	121 (27.1)
	3–4	165 (85.05)	29 (14.95)	194(43.4)
	>4	121 (91.67)	11 (8.33)	132 (29.5)
Region	Amhara	364 (87.9)	50 (12.1)	414 (92.6)
	Oromia	22 (84.6)	4 (15.4)	26 (5.8)
	Others	7		7 (1.6)
Residence of patients	Urban	312 (87.15)	46 (12.85)	358 (80.1)
	Rural	81 (91.01)	8 (8.99)	89 (19.9)
Marital status of women	Single	82 (91.1)	8 (8.9)	90 (20.13)
	Married	224 (89.6)	26 (10.4)	250 (55.92)
	Divorced	43 (76.8)	13 (23.2)	56 (12.53)
	Widowed	44 (86.27)	7 (13.73)	51 (11.42)
Educational status	Illiterate	90 (87.4)	13 (12.6)	103 (23)
	Can read and write	83 (89.25)	10 (10.75)	93 (20.8)
	Primary	113 (89.7)	13 (10.3)	126 (28.2)
	Secondary	69 (86.25)	11 (13.75)	80 (17.9)
	Tertiary	38 (84.4)	7 (15.6)	45 (10.1)
Occupational status	Farmer	39 (86.7)	6 (13.3)	45 (10.1)
	Merchant	44 (91.7)	4 (8.3)	48 (10.7)
	Governmental employee	59 (86.76)	9 (13.24)	68 (15.2)
	Non-governmental employee	48 (87.27)	7 (12.73)	55 (12.3)
	Day laborer	42 (84)	8 (16)	50 (11.2)
	Jobless	52 (89.66)	6 (10.34)	58 (13)
	Driver	4 (100)	0	4 0.9)
	Housewife	105 (88.24)	14(11.76)	119 (26.6)
Disclosure status	Disclosed	328 (89.37)	39 (10.63)	367 (82.1)
	Not disclosed	65 81.25)	15 (18.75)	80 (17.9)

Baseline Clinical, Laboratory, and ART Information of Adults on ART

A large proportion of the study participants, that is 169 (37.7%) of the study participants, were on WHO clinical stage II at baseline. More than three quarters (340; 76%) of the cohort had at least one opportunistic infection. The median CD4 count was 329 (IQR=187–578) cells/μL. The median hemoglobin value was 14 (IQR=12.1–15.2) g/dL. The vast majority (about 85%) of patients received Cotrimoxazole prophylaxis; and 16.5% were on anti-tuberculosis treatment (Table 2).

Table 2

Baseline Clinical, Laboratory, and Treatment-Related Characteristics of Adult HIV/AIDS Patients on ART in DBRH ART Clinic, North Showa, Amhara National Regional State, Ethiopia, 2019 (n=447)

Variables	Category	Vital Status at Last Contact		Total, n (%)
		Censored, n (%)	Death, n (%)
WHO staging	Stage I	149 (94.3)	9 (5.7)	158 (35.3)
	Stage II	153 (90.5)	16 (9.5)	169 (37.8)
	Stage III	76 (85.4)	13 (14.5)	89 (19.9)
	Stage IV	15 (48.4)	16 (51.6)	31 (7)
Opportunistic infections	No	83 (77.57)	24 (22.43)	107 (24)
	Yes	310 (91.2)	30 (8.8)	340 (76)
TB treatment during follow-up	Yes	57 (77)	17 (23)	74 (16.5)
	No	336 (90.1)	37 (9.9)	373 (83.5)
CD4 count	≥200 cells/μL	304 (96.2)	12 (3.8)	316 (70.7)
	<200 cells/μL	89 (67.9)	42 (32.1)	131 (29.3)
Body mass index	≤18.5	82 (67.8)	29 (32.2)	121 (27.1)
	18.5–25	239 (91.6)	22 (8.4)	261 (58.4)
	≥25	62 (95.4)	3 (4.6)	65 (14.5)
Functional status at base line	Working	325 (92.9)	25 (7.1)	350 (78.3)
	Ambulatory	67 (77.9)	19 (22.1)	86 (19.2)
	Bedridden	1 (9.1)	10 (90.9)	11 (2.5)
Hgb at base line	≥10 gm/dL	365 (93.8)	24 (6.2)	389 (87)
	<10 gm/dL	28 (48.3)	30 (51.7)	58 (13)
ART eligibility criteria	CD4 below 200	205 (87.6)	29 (12.4)	234 (52.4)
	WHO stage I, II, and III with TLC <1,200	85 (98.8)	1 (1.2)	86 (19.2)
	WHO stage IV	32 (68.1)	15 (31.9)	47 (10.5)
	Residence of catchment area	28 (93.3)	2 (6.7)	30 (6.7)
	No identified barriers for adherence	43 (86)	7 (14)	50 (11.2)
CPT	Yes	341 (89.3)	39 (10.7)	380 (85)
	No	52 (77.6)	15 (22.4)	67 (15)
Comorbidity	Yes	59 (65.6)	31 (34.4)	90 (20.1)
	No	334 (93.6)	23 (6.4)	357 (79.9)
Substance use	Yes	96 (82.8)	20 (17.2)	116 (26)
	No	297 (89.7)	34 (10.3)	331 (74)
Adherence	Good	373 (90.5)	39 (9.5)	412 (92.2)
	Fair	17 (65.4)	9 (34.6)	26 (5.8)
	Poor	3 (33.3)	6 (66.7)	9 (2)

Abbreviations: ART, antiretroviral therapy; CD4, cluster for differentiation; CPT, cotrimoxazole prophylaxis therapy; Hgb, hemoglobin; TB, tuberculosis; TLC, total lymphocyte count; WHO, World Health Organization.

Survival Status of Patients on ART

The mean survival time of patients was 63.7 months (95% CI=61.66–65.79) at 72 months of follow-up. The overall mortality rate in the cohort during the 1,291 person-years of observation (PYO) was 4.18 per 100 (95% CI=3.20–5.45) person-years follow-up. The cumulative incidence of death for this study was 54 (12.1%), with the confidence interval (95% CI=8.9–15.2%) of patients over 6 years. However, 393 (87.9%) of the study participants were censored, including 298 (66.7%) on ART, four (0.9%) who had stopped ART, 25 (5.6%) who were lost to follow-up, and 66 (14.8%) who transferred out. More than half(30; 55.6%) of the deaths occurred during the first year of treatment initiation, while 12 (22.2%) of the deaths occurred in the second year of follow-up.

Overall Survival of Patients on ART

In the present study, 447 patients on ART were followed up for a total of 72 months. The Kaplan–Meier survival estimation showed that the overall estimated survival rate after the initiation of HAART was 81.7% (95% CI=75.36–86.54%) at 72 months of follow-up. The estimated cumulative survival was 92.4%, 89.6%, 88.1%, 86.6%, 85.3%, and 81.7% at 12, 24, 36, 48, 60, and 72 months, respectively (Figure 1). The study revealed that the highest rate of mortality occurred during the first year of initiation of HAART.

Figure 1

Overall Kaplan–Meier estimates of patients starting ART in DBRH from January 1, 2013 to December 30, 2018.

Survival Function Among Different Groups of Patients on ART

The Log rank test was conducted to check for the existence of any significant differences in survival among the various levels of categorical variables considered in the study. The test statistics in this study showed significant associations in survival function for different categorical variables. Accordingly, the Kaplan–Meier analysis indicated significant evidence of differences in baseline opportunistic infections, functional status, comorbidity, WHO clinical staging, baseline hemoglobin, and baseline CD4 count. The Kaplan–Meier survival function indicated that those who had WHO clinical stage I, II, and III at baseline had a longer survival time than those with WHO clinical stage IV (34.3 months, 95% CI=23.03–45.6). This difference was statistically significant at P<0.0001. The mean survival time for those who had comorbidity and past opportunistic infection was 49.13 months (95% CI=42.70–55.56) and 57.1 months (95% CI=51.8–62.4), respectively. The survival time of patients with bedridden functional status was shorter than those with working and ambulatory functional status (7.26 months, 95% CI=3.75–10.76). This difference was statistically significant at P<0.0001.

The lowest survival probabilities were observed for patients with a bedridden functional status (0%), baseline hemoglobin <10 (36.74%), a baseline CD4 count <200 cells/μL (55.25%), and WHO stage IV disease (45.77%) (Table 3).

Table 3

Survival Time, Cumulative Survival Probability, Significance, and Log Rank Test for the Study Population According to Different Characteristics of Patients During 6 Years of Follow-Up (Kaplan–Meier Method) of HIV/AIDS Patients on ART in DBRH ART Clinic, North Showa, Amhara National Regional State, Ethiopia, 2019 (n=447)

Variables	Category	Mean Survival Time in Months (95% CI)	Overall, 6-Year Survival (%)	Log Rank Test (P-value)
Age of patient	15–24	68.64 (64.131–73.2)	93.8	0.1301
	25–34	64.68 (61.4–67.98)	79.79
	35–44	60.6 (56.46–64.74)	75.4
	≥45	64.27 (60.29–68.24)	87.2
Sex	Male	63.05 (59.31–66.79)	84.92	0.8217
	Female	63.90 (61.40–66.40)	78.81
Residence	Urban	63.30 (60.90–65.06)	79.78	0.3909
	Rural	65.54 (61.28–69.80)	90.09
Religion	Orthodox	63.70 (61.49–65.92)	82.12	0.6106
	Muslim	65.478 (60.00–70.95)	80.19
	Protestant	59.35 (45.6–73.09)	81.82
	Others	46.92 (12.2–81.58)	50
Educational status	Illiterate	63.88 (59.88–67.89)	76.15	1.70 (0.7899)
	Can read and write	64.48 (60.09–68.87)	85.83
	Primary	64.60 (60.90–68.42)	86.78
	Secondary	62.64 (57.60–67.67)	82.11
	Tertiary	59.33 (51.86–66.79)	71.67
Occupational statues	Farmer	61.10 (54.18–68.03)	85.08	2.31 (0.9409)
	Merchant	65.80 (60.04–71.57)	89.09
	Governmental employee	62.13 (56.30–68.02)	84.46
	Non-governmental employee	62.58 (56.16–69.00)	80.36
	Day laborer	61.40 (54.70–68.11)	79.39
	Jobless	65.65 (61.03–70.27)	72.28
	Housewife	64.19 (60.40–67.97)	81.76
Family size	≤2	64.33 (60.52–68.13)	78.64	2.65 (0.2662)
	3–4	61.89 (58.52–65.26)	79.56
	≥4	65.91 (62.64–69.20)	89.95
Marital status	Married	65.76 (61.67–69.86)	88.26	8.62 (<0.05)
	Single	64.82 (62.24–67.40)	85.32
	Widowed	62.16 (55.45–68.87)	80.52
	Divorced	56.25 (49.12–63.40)	50.89
Disclosure status	Disclosed	64.60 (62.40–66.78)	84.55	3.88 (<0.05)
	Not disclosed	59.68 (54.05–65.33)	69.59
WHO staging	Stage I	68.14 (65.70–70.59)	92.89	88.49 (<0.0001)
	Stage II	66.08 (63.32–68.84)	80.29
	Stage III	59.75 (53.99–65.50)	77.20
	Stage IV	34.30 (23.03–45.60)	45.77
Opportunistic infections	Yes	57.10 (51.80–62.40)	71.86	12.90 (<0.001)
	No	65.84 (63.75–67.93)	85.02
TB treatment during follow-up	Yes	56.11 (49.50–62.71)	74.11	10.18 (0.001)
	No	65.19 (63.12–67.26)	82.87
Comorbidity	Yes	49.13 (42.70–55.56)	58.42	54.53 (<0.0001)
	No	67.62 (65.89–69.35)	87.90
CD4 count	≥200 cells/μL	69.38 (67.93–70.83)	92.80	77.23 (<0.0001)
	<200 cells/μL	50.14 (44.79–55.50)	55.25
Body mass index	≤18.5	54.90 (49.58–60.22)	67.16	26.95 (<0.0001)
	18.5–25	66.27 (63.98–68.56)	84.24
	≥25	68.87 (65.49–72.25)	94.86
Functional status at base line	Working	67.25 (65.46–69.05)	86.94	201.57 (<0.0001)
	Ambulatory	56.41 (50.37–62.45)	71.42
	Bedridden	7.26 (3.75–10.76)	0.000
Hgb at base line	≥10 gm/dL	67.81 (66.19–69.43)	88.91	128.58 (<0.0001)
	<10 gm/dL	36.74 (28.33–45.15)	34.90
CPT	Yes	64.96 (62.87–67.04)	84.14	8.13 (<0.01)
	No	56.55 (49.83–63.27)	67.58
Substance use	Yes	60.39 (55.78–64.90)	71.16	4.03 (<0.05)
	No	64.80 (62.63–67.14)	85.47
Adherence	Good	65.49 (63.50–67.40)	85.38	49.03 (<0.0001)
	Fair	45.20 (34.79–55.61)	34.33
	Poor	29.73 (13.95–45.52)	25.40

Figure 2 shows that those who had no baseline opportunistic infections had better mean survival time, which was 65.84 months (95% CI=63.75–67.93), than those who had opportunistic infections at the baseline (57.1 months, 95% CI=51.8–62.4), this difference was statistically significant with P<0.001 .

Figure 2

The Kaplan–Meier survival curves compare survival time of patients starting ART by baseline OIs in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

The mean survival time for those who had clinical stage I, II, or III at baseline was longer than those in advanced clinical stage (IV) (34.3 months, 95% CI=23.03–45.6); this difference was statistically significant at P<0.0001 (Figure 3).

Figure 3

The Kaplan–Meier survival curves compare survival time of patients starting ART by baseline WHO clinical stage in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

The Kaplan–Meier graph shows that mean survival time for those who had working and ambulatory functional status was 67.25 months (95% CI=65.46–69.05) for working and 56.41 months (95% CI=50.37–62.45) for ambulatory, which was higher than the mean survival time of bedridden individuals (7.26 months, 95% CI=3.75–10.76). This difference was statistically significant at P<0.0001 (Figure 4).

Figure 4

The Kaplan–Meier survival curves compare survival time of patients starting ART by functional status in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

The Kaplan–Meier graph shows that the mean survival time for those who had hemoglobin level ≥10 mg/dL was 67.81 months (95% CI=66.19–69.43), which was higher than the mean survival time of individuals who had a hemoglobin level below 10 mg/dL (36.74 months, 95% CI=28.3–45.2). This difference was statistically significant at P<0.01 (Figure 5).

Figure 5

The Kaplan–Meier survival curves compare survival time of patients starting ART by baseline hemoglobin in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

Regarding the CD4 count, the mean survival time for those who had a CD4 count ≥200 cells/µL had a longer survival time than those with a CD4 count <200 cells/µL (50.14 months, 95% CI=44.8–55.5), which was statistically significant at P<0.0001 (Figure 6).

Figure 6

The Kaplan–Meier survival curves compare survival time of patients starting ART by baseline CD4 count in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

The Kaplan–Meier graph along with the Log rank test revealed that the mean survival time for those who had no comorbidity was longer (67.62 months, 95% CI= 65.89–69.35) than those who had comorbidity (49.13 months, 95% CI=42.70–55.56). This difference was statistically significant at P<0.0001 (Figure 7)

Figure 7

The Kaplan–Meier survival curves compare survival time of patients starting ART by comorbidity in DBRH, North Showa, Amhara National Regional State, Ethiopia from January 1, 2013 to December 30, 2018.

Predictors of Mortality

In the bivariable Cox Proportional Hazard regression model, marital status, disclosure status, substance use, baseline opportunistic infections, WHO clinical stage, functional status, baseline hemoglobin level, baseline CD4 count, body mass index, Cotrimoxazole prophylactic therapy adherence, and comorbidity were all associated with survival status (P<0.25).

In multivariable Cox regression analysis, those variables with a P-value<0.25 in the bivariable analysis were included. In the multivariable Cox proportional hazards model, seven variables were associated with the mortality of patients on ART.

The result of the multivariable analysis revealed that those who had opportunistic infection had a 1.86-times higher chance of death compared to those who had not (aHR=1.86, 95% CI=1.048–3.33). Patients who had comorbidity had a 2.56-times higher risk of dying than those who did not have comorbidity (aHR=2.56, 95% CI=1.39–4.74). Regarding WHO clinical staging, patients with stage III had a 2.88-times higher risk of dying thanthose who had stage I (aHR=2.88, 95% CI=1.204–6.9), and those who had stage IV had a 15.6-times higher risk of dying than those with stage I (AHR=15.6, 95% CI=6.61–36.94) (Table 4).

Table 4

Results of the Bi-Variable and Multivariable Cox Regression Analyses of HIV Patients Receiving ART in DBRH ART Clinic, North Showa, Amhara National Regional State, Ethiopia, 2019 (n=447)

Covariates	Category	Bivariate cHR (95% CI)	Multi-Variate aHR (95% CI)
Marital status	Single	1	1
	Married	1.18 (0.534–2.61)	1.51 (0.66–3.47)
	Divorced	2.826 (1.17–6.82)	3.475 (1.41–8.55)b
	Widowed	1.67 (0.61–4.61)	1.50 (0.54–4.15)
Substance use	Yes	1.75 (1.01–3.04)	1.59 (0.84–2.98)
	No	1	1
Disclosure	Yes	1	1
	No	1.80 (0.99–3.27)	1.24 (0.61–2.51)
Past OIs	Yes	2.58 (1.51–4.43)	1.86 (1.05–3.33)a
	No	1	1
TB treatment	Yes	2.47 (1.39–4.40)	1.65 (0.85–3.19)
	No	1	1
CPT	Yes	1	1
	No	2.32 (1.28–4.21)	1.13 (0.5–2.57)
Comorbidity	Yes	5.97 (3.48–10.24)	2.56 (1.39–4.74)b
	No	1	1
Baseline Hgb	≥10 mg/dL	1	1
	<10 mg/dL	11.75 (6.85–20.15)	4.7 (2.25–9.62)c
Baseline CD4	≥200 cells/μL	1	1
	<200 cells/μL	10.22 (5.38–19.44)	4.710 (2.28–9.75)c
Functional status	Working	1	1
	Ambulatory	3.545 (1.950–6.443)	1.03 (0.47–2.26)
	Bedridden	42.804 (94.318)	3.07 (1.11–8.480)a
WHO clinical staging	Stage I	1	1
	Stage II	1.690 (0.747–3.824)	1.659 (0.718–3.831)
	Stage III	3.334 (1.420–7.827)	2.88 (1.204–6.899)a
	Stage IV	16.312 (7.140–37.265)	15.6 (6.609–36.948)c
ARV adherence	Good	1	1
	Fair	4.419 (2.134–9.151)	0.972 (0.342–2.763)
	Poor	9.260 (3.906–21.953)	2.366 (0.759–7.377)
BMI	≤18.5	6.764 (2.058–22.232)	1.777 (0.500–6.322)
	18.5–25	2.074 (0.621–6.932)	1.449 (0.423–4.969)
	≥25	1	1

Notes: aSignificant (P-value<0.05), bSignificant (P-value<0.001), cSignificant (P-value<0.0001.

Discussion

This retrospective cohort study was aimed to assess the survival and predictors of mortality among adult HIV/AIDS patients who initiated highly active antiretroviral therapy. At the end of follow-up, 54 patients were dead and 393 patients were censored. That resulted in a cumulative incidence of deaths of 12.1% over 6 years. This finding is in line with studies conducted in the Somali Region, Eastern Ethiopia, which reported 11.1%,13 and South Omo, Ethiopia, which reported 10%.19 However, the total number of deaths that occurred in this study was higher than other studies conducted in southwest Ethiopia (6.4%)22 and Northwest Ethiopia (4.2%).8 But, some studies reported higher findings compared with this study in the ART Center of MKCG Medical College, Berhampur, Ganjam, and Odisha (21.33%)25 and Debre Markos (43%).20 The discrepancy of results among studies might be due to differences in sample, in length of the study period, and differences in initiation of anti-retro-viral therapy.

The current study revealed the overall mortality rate of patients on ART during 72 months follow-up was 4.18/100 person-years. This finding is in line with studies conducted by Dilla University Hospital,11 and seven university teaching hospitals in Ethiopia,12 where the incidence rates per person-year were 3.0 and 5.4, respectively. However, this finding is much higher than the findings reported in Debre-Markos Referral hospital,20 Jinka Hospital, South Omo Zone, Ethiopia,19 and Jimma University Teaching Hospital, South-West Ethiopia,22 to which the mortality rates were reported as 1.9, 1.75, and 2.17 per person-years, respectively. The observed difference in mortality rates might be due to the difference in sample size, duration of the study period, and the time duration each cohort contributed.

The presence of opportunistic infection at the time of ART initiation was found to be an important predictor of survival. Accordingly, patients who have an opportunistic infection at ART initiation are 1.86-times more likely to die as compared to those who do not have an opportunistic infection on ART initiation. Studies conducted at Fiche hospital in North Showa, Oromia region, Ethiopia, a selected public hospital in Harar, eastern Ethiopia, and India supported that the presence of opportunistic infection increases the probability of death.16,26,27 This might be because opportunistic infections may increase the risk of mortality in the first few months after initiating ART due to immune reconstitution syndrome, a paradoxical worsening or recurrence of opportunistic infection symptoms as a result of the rapid immunological recovery.28

The current study revealed that patients with baseline WHO clinical stage III and IV were 2.88-times and 15.6-times more likely to die compared to patients with WHO clinical stage I or II, respectively. Different studies supported this idea.20,27 This might be due to the fact that patients died mostly because of their late initiation of ART when they had the worst health condition. Early initiation before the advancement of the disease is recommended as soon as the confirmation of HIV diagnosis, which helps decrease the morbidity and mortality of HIV/AIDS. Besides, people with advanced HIV disease require closer follow-up during the initial period of receiving ART to monitor the response to ART and to identify signs and symptoms of possible immune reconstitution inflammatory syndrome.

This study showed that patients who were bedridden at ART initiation were 3.069-times more likely to die compared to the patients with working functional status at treatment initiation. This finding is supported by the study conducted in Jimma university teaching hospital, Khartoum State, Sudan, and Eastern Ethiopia in which bedridden patients were 2.5-, 4.765-, and 4.09-times more likely to die than those patients with working and ambulatory functional status, respectively.22,29,30 This could be due to poor immunologic response, mainly failure to restore CD4 cells to 500 cells/µL despite being virally suppressed.

This study indicated that the baseline hemoglobin level <10 gm/dL was found to be a significant predictor of death among HIV positive patients on ART. Accordingly, patients who had a hemoglobin level <10 gm/dL were 4.7-times more likely to die as compared to those who had hemoglobin levels greater than or equal to 10 gm/dL. This finding is supported by previous studies that have been conducted in Aksum, Northern Ethiopia.9 Maybe because anemia is one of the markers of advanced disease and can increase the mortality of patients.

This study revealed that patients who had a CD4 count <200 cells/µL were found to be 4.7-times more likely to die than to those who have a CD4 count ≥200 cells/µL. A study conducted in Jimma university teaching hospital indicated that patients who were on ART with CD4 <200 cells/µL were 1.3-times more likely to die when compared to those whose CD4 was ≥200 cells/µL.22

This discrepancy might be due to a difference in sample size and the eligible age groups for the study. Above all, the reduction of CD4 count decreases the immunity of patients, exposing them to opportunistic infections and predispose to micronutrient deficiency like iron which in turn causes the reduction of the amount of hemoglobin, which was an important predictor for mortality of patients initiated ART. Moreover, PLWH who have a CD4 cell count below 200 are at high risk of developing serious illnesses.

The current study showed that patients who had comorbidity have a 2.56-times higher hazard of mortality than those who had no comorbidity. This could be due to the fact that comorbidities complicate caring infrastructures for HIV-infected patients, because patients with multiple diseases and on complex pharmacological treatments are particularly difficult to manage, both in chronic and acute phases.

Limitation of the Study

Selection bias was possibly introduced due to the fact that patients with incomplete records of variables or charts which were lost for some patients were excluded. Therefore, those study subjects whose charts were not included in the study and with missing values may undermine the result if it is related with death.

Conclusion

In the current study, a total of 54 (12.1%) patients on ART died during the follow-up period. Hence, the overall incidence rate was 4.18 per 100-person years with an overall mean survival time of 63.7 months. Close follow-up and monitoring should be given to patients who have baseline CD4<200 cells/µL, opportunistic infections at baseline, patients with hemoglobin <10 gm/dL, functional status of bedridden, and those who have comorbidity. Special emphasis and close follow-up should be given to patients who had baseline stage III and IV disease. Further predictors of mortality of patients on ART needs to be studied with another strong (prospective) study design.